Integrated drug profiling and CRISPR screening identify essential pathways for CAR T cell cytotoxicity | Blood | American Society of Hematology
You do not currently have access to this content.
You do not currently have access to this content.
Key PointsThis nationwide study shows that major bleeding and thromboembolic events are more frequent in MF than previously described in other MPNs.The use
Key Points. Patients with large B cell lymphoma frequently experience infections within 100 days following CD19 CAR T-cell therapy.Infectious complications
Key PointsTriplet regimens provide longer TTNT and improved OS than doublets in Octos.The introduction of daratumumab-based regimens resulted in significan
Key PointsHigh surface expression of cMPL is a hallmark feature of LT-HSCs within the adult human CD34+ HSPC subset.Anti-cMPL immunotoxin selectively deple
Key PointsTriplet regimens provide longer TTNT and improved OS than doublets in Octos.The introduction of daratumumab-based regimens resulted in significan
Phosphoinositide 3-kinase gamma (PI3Kγ), long recognized as a cell-extrinsic immunotherapy target in solid tumors, is now emerging as a cell-intrinsic depe
Background. The American Society of Hematology (ASH) guidelines on treatment of pediatric venous thromboembolism (VTE) were published in 2018. In the last
Abstract. The disease shift of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL), so-called Richter transformation (RT), is a cat
In this issue of Blood, Wuliji and colleagues evaluate the relationship between social determinants of health and access to hematopoietic transplantation i
In this Letter to the Editor, Khushali Jhaveri, MD, reflects on her experience as an international medical graduate from India working in the U.S. A…